media – Page 103 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Novo Nordisk and Ali Health launch strategic cooperation to promote digital upgrade of chronic disease management

China Securities Journal China Securities Network News (Reporter Fu Suying) Novo NordiskNovo Nordisk and Ali Health recently announced a strategic partnership. The two parties will rely on Novo Nordisk ‘s more than 100 years of professional experience and innovative treatment plans in the field of chronic diseases, as well as Ali Health ‘s innovative business model in the field of Internet medical care, to jointly create a one-stop weight management knowledge and service area to help the public understand healthy weight standards, master weight management methods, manage weight scientifically, and assist in one-stop diagnosis and treatment of diabetes and digital transformation and upgrading of chronic disease management. It is reported that the one-stop weight management knowledge and service zone jointly created by Ali Health and Novo Nordisk will deeply integrate the advantages of both parties to provide patients with a smart medical solution that integrates disease knowledge popularization, healthy weight ...
- Source: drugdu
- 257
- June 20, 2025
New psoriasis drug ASC50 completes first trial dosing in the U.S.

According to CSI Smart Finance , Ascletis Pharmaceuticals-B (01672) announced in the morning of June 18 that the board of directors announced that the first batch of healthy subjects have been dosed in the randomized, double-blind, placebo-controlled Phase I clinical trial of ASC50 in the United States. The trial aims to evaluate the safety, tolerability and preliminary efficacy of ASC50 in the treatment of psoriasis (NCT07024602). ASC50 is an oral small molecule interleukin-17 (IL-17) targeted inhibitor independently developed by Ascletis. IL-17 has been fully biologically validated in various autoimmune and inflammatory diseases such as psoriasis and has mature commercial value. Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis, said: “We are pleased to announce that the first patient has been dosed in the clinical trial of ASC50 for the treatment of psoriasis ahead of schedule, starting the clinical development of this drug candidate. We look forward to obtaining the ...
- Source: drugdu
- 166
- June 20, 2025
Lung cancer market battle is underway again

Recently, Ibtrozi (taletrectinib) developed by Nuvation Bio was approved by the US FDA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The drug is a highly selective, new-generation oral ROS1 tyrosine kinase inhibitor (TKI). In key trials, Ibtrozi demonstrated high response rates and lasting efficacy, and has the ability to penetrate the blood-brain barrier. Coupled with a clear and controllable safety profile, it is expected to become a new standard for targeted treatment of this type of lung cancer. It is worth noting that the drug was approved for marketing in China in December 2024 for the first-line and second-line treatment of adult patients with ROS1-positive locally advanced or metastatic NSCLC, and Innovent Biologics is responsible for commercialization. Potential BIC Therapies Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is one of the most ...
- Source: drugdu
- 168
- June 20, 2025
AstraZeneca and CSPC Pharmaceuticals reach $5.3 billion partnership

On June 13, AstraZeneca and CSPC Pharmaceutical Group reached a strategic cooperation. The two parties will focus on high-priority targets and work together to promote the discovery and development of new oral drug candidates. CSPC Pharmaceutical Group will conduct research using its AI engine dual-driven efficient drug discovery platform. The platform uses AI technology to analyze the binding mode between target proteins and existing compound molecules and conduct targeted optimization, aiming to screen out small molecules that are highly efficient and have excellent development potential. Under the agreement, CSPC Pharmaceutical Group will receive an upfront payment of US$110 million and will be eligible to receive potential research and development milestone payments of up to US$1.62 billion and potential sales milestone payments of up to US$3.6 billion, as well as potential single-digit sales commissions based on annual net sales of the relevant products. As a global pharmaceutical giant, AstraZeneca continues to ...
- Source: drugdu
- 144
- June 20, 2025
【EXPERT Q&A】Is CDMO service for medical devices reliable?

Drugdu.com expert’s response: Medical device Contract Development and Manufacturing Organization (CDMO) services are reliable when they operate with strong compliance, technical expertise, and resource integration capabilities. However, potential risks such as intellectual property (IP) protection, industry trust, and policy changes should be noted. Below is a detailed analysis: Advantages of Medical Device CDMO Services High Specialization: Medical device CDMO companies typically possess extensive professional knowledge and practical experience, enabling them to provide one-stop services for medical device enterprises, ranging from product R&D and manufacturing to technical solutions. Cost Reduction: By outsourcing R&D and production processes, medical device enterprises can reduce investments in equipment, personnel, and facilities, thereby lowering R&D costs. Meanwhile, CDMO companies can leverage their advantages in large-scale production to reduce manufacturing costs and offer more competitive pricing to clients. Accelerated Market Launch: CDMO companies have professional R&D teams and rich practical experience, enabling them to provide efficient R&D ...
- Source: drugdu
- 239
- June 20, 2025
Can We Truly Cure Multiple Myeloma? Experts Say Yes

The Spanish Society of Hematology and Hemotherapy (SEHH) held its ninth “HematoAvanza” Outreach Conference at the Pazo de San Lorenzo in Santiago, Spain. The event brought together hematologists, patients, science communicators, and journalists to explore key advances in hematologic disorders, with multiple myeloma taking center stage in the discussions. María Victoria Mateos, MD, PhD, president of the SEHH, stated that “we are at the point where we can talk about curing patients with myeloma.” Mateos is also the director of the Myeloma Program and Clinical Trials Unit at the Salamanca University Hospital and an associate professor of medicine at the University of Salamanca, Salamanca, Spain. Paradigm Shift Until now, multiple myeloma has been considered an incurable disease. However, new treatments, new therapeutic strategies, and early diagnosis are making it possible to achieve a functional and even complete cure in an increasing proportion of patients. Mateos explained that the definition of ...
- Source: drugdu
- 183
- June 19, 2025
Blood Pressure Diet Helps Type 2 Diabetics

By Dennis Thompson HealthDay ReporterTUESDAY, June 17, 2025 (HealthDay News) — A diet meant to lower blood pressure also can be effective in treating type 2 diabetes after a few tweaks, a new clinical trial indicates. The DASH (Dietary Approaches to Stop Hypertension) diet effectively treated high blood pressure among type 2 diabetics, researchers reported recently in JAMA Internal Medicine. “A lot of people are interested in controlling diabetes and their blood pressure through diet and other lifestyle changes,” said senior researcher Dr. Lawrence Appel, a professor of medicine at Johns Hopkins University School of Medicine. “Most people in this study were taking more than one blood pressure medication, but we found that you can lower it further with dietary change,” Appel added in a news release. “Blood pressure is one of the most important numbers to control because the higher the number, the higher the risk of stroke and ...
- Source: drugdu
- 151
- June 19, 2025
Upgraded patent disputes with Platinum and Baiaosaitu; Rongchang Biotech’s Taitacept has been recognized as an orphan drug by the European Union

NO.1 and Platinum, Baiaosaitu Patent Dispute Escalation On the 16th, Hebo Pharmaceutical announced the latest progress of its core patent protection action to the public. The China National Intellectual Property Administration made an examination decision on June 5, 2025 to maintain the patent right of “binding molecule” with platinum medicine. The patent involves the method of preparing whole human heavy chain only antibody (HCAb) using transgenic animals, and this decision is made in response to the request for invalidation made by BIOSAITO (Beijing) Medical Technology Co., Ltd. Comment: From the previous actions, it is clear that Hebo Pharmaceutical regards this patent protection as a key measure to safeguard its core assets. The “binding molecule” patent of Platinum Pharmaceuticals is its Harbour Mice ® The core of the platform, which has established partnerships with multiple well-known pharmaceutical companies worldwide, has significant commercial value. NO.2 Yunnan Baiyao JZ-14 Capsules Obtained Clinical ...
- Source: drugdu
- 139
- June 19, 2025
Eighteen years of hard work! Breaking through with Xinkening 9, rewriting the global HPV vaccine landscape

Recently, the domestically produced nine valent HPV vaccine “Xinkening ® The approval of “9” for listing marks a crucial step for China in the field of high-end vaccine research and development. This vaccine was jointly developed by Professor Xia Ningshao’s team from Xiamen University and Wantai Biotechnology. It took 18 years to overcome numerous technical difficulties and opened up an original path for China in the international vaccine technology system. Its birth is not only an industrial breakthrough, but also an enhancement of national public health capabilities. Faced with cervical cancer, a serious threat to women’s health, China finally has an internationally advanced local protection plan. Cervical cancer has long been in the forefront of the incidence rate of malignant tumors among Chinese women, with more than 100000 new cases each year. Although vaccines are the most effective primary prevention method, the heavy reliance on expensive imported vaccines in ...
- Source: drugdu
- 210
- June 19, 2025
WALVAX and Zhiyu Biosciences reach strategic cooperation

On June 18, WALVAX announced that the company has established a strategic partnership with Shanghai Zhiyu Biotechnology Co., Ltd. (“Zhiyu Bio” for short). The core of this strategic cooperation between the two parties is to apply Zhiyu Bio’s AI modeling combined with physical simulation biocomputing technology to WALVAX’s human vaccine research and development field, focusing on using AI technology to accelerate the process development process such as protein (including enzyme) discovery and design, providing AI biocomputing platform licensing services to build intelligent R&D infrastructure, and providing deeply customized AI biocomputing solutions for the needs of specific vaccine products. https://finance.eastmoney.com/a/202506183433263559.html
- Source: drugdu
- 112
- June 19, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.